you attend the clinic for the first time (week 0). during this visit a series of measurements are taken, including a blood test called hba1c that shows your average blood sugar over the past few months, weight, blood pressure, and other routine labs.

you also receive information about the study drugs and are asked to sign consent forms that allow you to receive the assigned medication.

after the baseline visit you are randomly assigned to receive either ubt251 at a study‑determined dose, the comparator drug semaglutide (0.5 mg) or a matching placebo.

the first dose is given as a subcutaneous injection, which means the medication is placed just under the skin using a pre‑filled pen or syringe.

you self‑administer, or have a nurse administer, a single injection of the assigned study medication once every week. the injection is performed under the skin (subcutaneous) and the dose remains the same each week during this early period.

if you are assigned to semaglutide, the dose is 0.5 mg per injection. if you are assigned to ubt251, the exact amount is set by the study protocol and is also given once weekly. the placebo looks identical but contains no active drug.

you return to the clinic at weeks 2, 4, 8 and 12 for safety checks. during each visit blood samples are taken to monitor hba1c, fasting plasma glucose, kidney function, and other safety parameters.

any side effects or concerns are recorded, and the study team confirms that you are continuing the weekly injections correctly.

based on the data collected up to week 12, the study determines a maintenance dose of ubt251 for each participant who receives the active drug. from week 13 onward you continue to receive the same weekly injection, now at the maintenance dose.

participants receiving semaglutide or placebo continue with the same weekly dose they have been using.

at week 16 and again at week 28 you attend a clinic visit where the primary effectiveness measure – the change in hba1c from the start of the maintenance dose – is evaluated.

additional measurements such as body weight, blood pressure, and laboratory tests are repeated to track any changes.

the last clinic visit occurs at week 40. during this visit a complete set of assessments is performed, including the final hba1c measurement, weight, waist circumference, cholesterol panel, kidney function, and any remaining safety labs.

you receive a final injection of the study medication (or placebo) and the study drug is discontinued after this visit.